Atezolizumab subcutaneous preparation (Tecentriq Hybreza) drug encyclopedia and listing status in China

As an innovative immunotherapy drug, atezolizumab subcutaneous preparation has attracted much attention in the treatment of non-small cell lung cancer in recent years. The drug combines atezolizumab, a PD-L1 inhibitor, with hyaluronidase through subcutaneous injection, achieving a more convenient and efficient treatment.

The subcutaneous formulation of atezolizumab was developed based on in-depth scientific research. PD-L1 is a protein expressed on the surface of tumor cells. By binding to the PD-1 receptor on immune cells, it inhibits the activation and proliferation of immune cells, thereby helping tumor cells evade attack by the immune system. Atezolizumab, as a monoclonal antibody, can specifically bind to PD-L1 and block its interaction with PD-1, thereby reactivating immune cells and enhancing the immune system's ability to kill tumor cells. The addition of hyaluronidase helps the dispersion and absorption of the drug in the subcutaneous tissue, further improving the bioavailability and efficacy of the drug.

In clinical application, the subcutaneous formulation of atezolizumab has demonstrated good safety and efficacy. Compared with intravenous infusion dosage forms, subcutaneous preparations significantly shorten the administration time, reduce patients' pain and discomfort, and improve treatment compliance and quality of life.

In China, the launch of atezolizumab subcutaneous preparations has attracted much attention. As the incidence of cancer in China continues to rise, patients' demand for efficient and convenient immunotherapy drugs is increasing. However, at present, the subcutaneous formulation of atezolizumab has not yet been approved, but it is expected to be approved for marketing in the future. This will bring new treatment hope to the vast number of Chinese cancer patients and further improve the effectiveness of cancer treatment and quality of life.

In summary, atezolizumab subcutaneous preparation, as an innovative immunotherapy drug, has broad application prospects in the field of cancer treatment. With the widespread promotion and application of this drug around the world, it is believed that it will bring good news to more cancer patients. At the same time, we also look forward to the advent of more innovative drugs in the future to jointly promote the development of the field of cancer treatment.

Reference materials:https://www.drugs.com/search.php?searchterm=TECENTRIQ+HYBREZA